ReviewClinical pharmacology and therapeutics2012
A perspective on efflux transport proteins in the liver.
Review in Clinical pharmacology and therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 107 citations in OpenAlex.
- Impact of pharmacogenetics on variability in exposure to oral vinorelbine among pediatric patients: a model-based population pharmacokinetic analysis.Cancer chemotherapy and pharmacology · 2022Trial
- Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics.Clinical and translational science · 2021Trial
- Scientific Report on consumer health-based guidance values for trifluoroacetic acid.EFSA journal. European Food Safety Authority · 2026Article
- Hepatoprotective Potential of Curcumin in the Prevention of Liver Dysfunction in a Porcine Model.Nutrients · 2026Review
- Multidrug Resistance-Associated Proteins 3 and 5 Play a Role in the Hepatic Transport of Mercuric Conjugates of Glutathione.International journal of molecular sciences · 2025Article
- Overcoming Challenges in Small-Molecule Drug Bioavailability: A Review of Key Factors and Approaches.International journal of molecular sciences · 2024Review
- Does Bisphenol A (BPA) Exposure Cause Human Diseases?Biomedicines · 2024Review
- Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells.Biopharmaceutics & drug disposition · 2022Article
- Mouse precision-cut liver slices as an ex vivo model to study drug-induced cholestasis.Archives of toxicology · 2022Article
- Impact of pregnancy related hormones on drug metabolizing enzyme and transport protein concentrations in human hepatocytes.Frontiers in pharmacology · 2022Article
- Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats.Molecular pharmaceutics · 2021Article
- High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids.Gastroenterology · 2021Article
- Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance.Nature communications · 2021Article
- Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey.PloS one · 2021Article
- Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study.Drugs in R&D · 2020Article
- PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.Journal of pharmacokinetics and pharmacodynamics · 2020Article
- Activation of WNT/Beta-Catenin Signaling and Regulation of the Farnesoid X Receptor/Beta-Catenin Complex After Murine Bile Duct Ligation.Hepatology communications · 2019Article
- Development of Bifunctional Three-Dimensional Cysts from Chemically Induced Liver Progenitors.Stem cells international · 2019Article
- Transport of Bupropion and its Metabolites by the Model CHO and HEK293 Cell Lines.Drug metabolism letters · 2019Article
- Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.Clinical pharmacology and therapeutics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Detailed knowledge regarding the influence of hepatic transport proteins on drug disposition has advanced at a rapid pace over the past decade. Efflux transport proteins located in the basolateral and apical (canalicular) membranes of hepatocytes play an important role in the hepatic elimination of many endogenous and exogenous compounds, including drugs and metabolites. This review focuses on the role of these efflux transporters in hepatic drug excretion. The impact of these proteins as underlying factors for disease is highlighted, and the importance of hepatic efflux proteins in the efficacy and toxicity of drugs is discussed. In addition, a brief overview of methodology to evaluate the function of hepatic efflux transport proteins is provided. Current challenges in predicting the impact of altered efflux protein function on systemic, intestinal, and hepatocyte exposure to drugs and metabolites are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.